 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- A T cell Engager targeting Cancer Associated Fibroblast inhibits Tumor Growth and modulates the Tumor Microenvironment (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1438;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- | paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Metabolic and Immunological Implications of MME+CAF-Mediated Hypoxia Signaling in Pancreatic Cancer Progression: Therapeutic Insights and Translational Opportunities. (Pubmed Central) - Sep 29, 2024
The study findings highlighted the significant role of MME+CAF in pancreatic cancer progression by shaping the TME and influencing key pathways. Targeting MME presented a promising strategy to combat the disease, with potential implications for therapeutic interventions aimed at disrupting MME+CAF functions and enhancing the efficacy of pancreatic cancer treatments.
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg.
Biomarker, Journal: MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation. (Pubmed Central) - Sep 24, 2024
Our findings highlight the significant potential of MIR4435-2HG as a highly promising biomarker for TNBC. Targeting MIR4435-2HG could represent an appealing therapeutic approach for TNBC.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Nubeqa (darolutamide) / Bayer, Orion Corp
Journal: Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models. (Pubmed Central) - Sep 21, 2024
Targeting MIR4435-2HG could represent an appealing therapeutic approach for TNBC. CAFs exert a protective effect on cancer cells and should be included in the in
- Venclexta (venetoclax) / Roche, AbbVie
Therapeutic Targeting of Lung Cancer-Associated Fibroblasts Mitigates Mediastinal Lymphatic Dissemination in Non-Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2486;
The efficacy of CAF inhibitors, namely ABT-199 and NNMTi (Nicotinamide N-Methyltransferase inhibitor), was assessed to determine their ability to inhibit lymphangiogenesis and prevent mediastinal lymph node metastasis...Conclusions : Lung CAFs promote tumor-associated lymphangiogenesis and mediastinal lymph node metastases in NSCLC orthotopic xenograft model. The strategy of targeting lung CAFs holds promise in limiting cancer cells spread via lymphatics, particularly in CAFs-rich NSCLC scenarios.
- | Turalio (pexidartinib) / Daiichi Sankyo
Preclinical, Journal, Checkpoint inhibition: Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts. (Pubmed Central) - Jul 13, 2024
RNA-seq following combination therapy showed activation of tumor immunity. In summary, CAFs are involved in the induction and mobilization of M2 macrophage differentiation in the CRC tumor immune microenvironment, and the combination of cancer immunotherapy and PLX3397 may represent a novel therapeutic option for CRC.
- || Review, Journal: Boosting antitumor efficacy of nanoparticles by modulating tumor mechanical microenvironment. (Pubmed Central) - Jun 15, 2024
Finally, prospects and challenges for further clinical applications of mechano-modulating strategies to enhance the therapeutic efficacy of nanomedicines are discussed. This review may provide guidance for the rational design and application of nanoparticles in clinical settings.
- | Journal, IO biomarker: Colorectal cancer-associated fibroblasts inhibit effector T cells via NECTIN2 signaling. (Pubmed Central) - Jun 15, 2024
Analysis of clinical datasets showed that NECTIN2 expression is a poor prognostic factor in CRC and other tumors. In conclusion, we identified a new class of immuno-suppressive CAF with features rendering them a potential target for future immunotherapies.
- | erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys
Journal: Exosomal lncRNA ROR1-AS1 from cancer-associated fibroblasts inhibits ferroptosis of lung cancer cells through the IGF2BP1/SLC7A11 signal axis. (Pubmed Central) - Jun 11, 2024
In conclusion, we identified a new class of immuno-suppressive CAF with features rendering them a potential target for future immunotherapies. CAFs secrete exosomal ROR1-AS1 to promote the expression of SLC7A11 by interacting with IGF2BP1, thereby inhibiting ferroptosis of lung cancer cells.
- | paclitaxel / Generic mfg., dasatinib / Generic mfg.
Journal: Bioresponsive nanocomplex integrating cancer-associated fibroblast deactivation and immunogenic chemotherapy for rebuilding immune-excluded tumors. (Pubmed Central) - May 27, 2024
Moreover, GNC treatment exhibited remarkable immunostimulatory efficacy, including CD8+ T cell expansion and PD-L1 downregulation, facilitating immune checkpoint blockade therapy. In summary, the integration of CAF deactivation and immunogenic chemotherapy using the GNC nanoplatform holds promise for rebuilding immune-excluded tumors.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Rhein potentiates doxorubicin in treating triple negative breast cancer by inhibiting cancer-associated fibroblasts. (Pubmed Central) - Apr 22, 2024
This removal of stromal barrier facilitated the antitumor efficacy of DOX. Altogether, this study demonstrated for the first time that Rhe could inhibit tumor tissue fibrosis and synergize DOX to treat TNBC.
- | galunisertib (LY2157299) / Eli Lilly, IOA-289 / iOnctura
Journal, Stroma: Autotaxin secretion is a stromal mechanism of adaptive resistance to TGF? inhibition in pancreatic ductal adenocarcinoma. (Pubmed Central) - Jan 3, 2024
These results establish that autotaxin secretion by CAFs is increased by TGF? inhibition and that circulating autotaxin levels predict response to the combination treatment approach of gemcitabine plus galunisertib.
- | Journal, IO biomarker: An Exosome-Related Long Non-coding RNA (lncRNA)-Based Signature for Prognosis and Therapeutic Interventions in Lung Adenocarcinoma. (Pubmed Central) - Nov 30, 2023
Conclusion Our findings indicate that ExoLncSig holds promise as a valuable prognostic marker in LUAD. Furthermore, the immunogenic properties of ExolncRNAs may pave the way for the development of a therapeutic vaccine against LUAD.
- | Journal: Magnetic Metal-Organic Framework-Based Nanoplatform with Platelet Membrane Coating as a Synergistic Programmed Cell Death Protein 1 Inhibitor against Hepatocellular Carcinoma. (Pubmed Central) - Nov 22, 2023
Combination therapy with PmMN@Om&As and ?-PD-1 resulted in a tumor suppression rate of 84.15% and prolonged the survival time of mice. Our study provides a promising approach to improving the antitumor effect of immunotherapy in HCC.
- | Journal: Salvianolic acid B-loaded polydopamine-modified hollow mesoporous organic silica nanoparticles for treatment of breast cancer metastasis via suppressing cancer-associated fibroblasts. (Pubmed Central) - Nov 17, 2023
This inhibitory effect may be related to the inhibition of CAFs. In vivo experiments demonstrated that SAB@HMON-PDA can inhibit lung metastasis of breast cancer by inhibiting CAFs, and its effect was more significant than that of free SAB.
- | Journal: Self-Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer. (Pubmed Central) - Sep 16, 2023
Antitumor study with the self-adaptive nanoregulator elicited persistent antitumor immunity and remarkable antitumor performance in both Panc02 and KPC tumor models in vivo. Taken together, the PDC-based self-adaptive nanoregulator might provide a novel avenue for enhanced PDAC immunotherapy.
- | Preclinical, Journal: Retraction: Exosomal miRNA-34 from cancer-associated fibroblasts inhibits growth and invasion of gastric cancer cells in vitro and in vivo. (Pubmed Central) - Aug 28, 2023
Taken together, the PDC-based self-adaptive nanoregulator might provide a novel avenue for enhanced PDAC immunotherapy. No abstract available
- ARC2-001 / Arontier
ARC2-001 inhibits cancer-associated fibroblast-dependent cancer stem cell populations by disrupting cancer-stroma interactions. (Section 36; Poster Board #17) - Mar 14, 2023 - Abstract #AACR2023AACR_6766;
Surprisingly, we observed that both tumor growth and cancer metastasis were suppressed in the combination treatment group. This indicates that ARC2-001 dramatically increases the effectiveness of existing anticancer drugs and can be used as an additional combination therapy for colorectal cancer chemotherapy.
- hydroxychloroquine / Generic mfg., gemcitabine / Generic mfg.
Combination of hydroxychloroquine, paricalcitol and gemcitabine modulate autophagy and anti-tumor responses in pancreatic ductal adenocarcinoma (Section 14; Poster Board #8) - Mar 14, 2023 - Abstract #AACR2023AACR_4894;
The combination of GPH creates higher cytotoxicity (decreased proliferation, clonogenicity and increased autophagy positive cells; p<0.001) in PDAC cell lines and tumor regression in vivo. Collectively, this investigation offers mechanistic insight into the cytotoxicity initiated by GPH and suggests further evaluation of its utility for PDAC therapy is warranted.